Search

Search Results

• BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT IN SPLENIC MARGINAL ZONE LYMPHOMAS of ELDERLY PATIENTS.

  Roberto Castelli

  e2016030

  2016-07-01

  https://doi.org/10.4084/mjhid.2016.030

  5319

  PDF: 1008

  HTML: 2040

• ITPA POLYMORPHISMS AND THE INCIDENCE OF TOXICITIES IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA

  Patpetra Svasdisant, Waraporn Glomglao, Preeyanun Siraprapapat, Wiyakan Inthararujikul , Kalaya Tachavanich, Chetsada Boonthimat, Sakkarin Ardsiri, Kochpinchon Chansing, Suwimon Sriprach , Sasima Tongsai , Phakatip Sinlapamongkolkul , Kleebsabai Sanpakit , Jassada Buaboonnam

  e2023024

  2023-02-28

  https://doi.org/10.4084/MJHID.2023.024

  1157

  PDF: 977

  HTML: 392

• IMMUNOLOGICAL DEREGULATION IN HODGKIN’S DISEASE

  Francesco Di Raimondo, Giorgio La Nasa

  e2014039

  2014-05-29

  https://doi.org/10.4084/mjhid.2014.039

  2277

  PDF: 1002

  HTML: 1981

• OUTCOME AND TOXICITY PATTERNS IN CHILDREN AND ADOLESCENTS WITH NON-HODGKIN LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE

  Paola Angelini, Laura Rodriguez, Mohammed Zolaly, Ahmed Naqvi, Sheila Weitzman, oussama Abla, Angela Punnett

  e2018020

  2018-03-01

  https://doi.org/10.4084/mjhid.2018.020

  2990

  PDF: 860

  HTML: 426

• CLINICAL ANALYSIS AND OPTIMIZATION OF POST-REMISSION THERAPY FOR ACUTE MYELOID LEUKEMIA PATIENTS WITH MINIMAL RESIDUAL DISEASE AS DETERMINED BY FLOW CYTOMETRY

  Daichi Inoue, Hayato Maruoka, Takayuki Takahashi

  e2010020

  2010-08-05

  https://doi.org/10.4084/mjhid.2010.020

  1333

  PDF: 768

  HTML: 1240

• PROGNOSTIC SIGNIFICANCE OF NRAS GENE MUTATIONS IN CHILDREN WITH ACUTE MYELOGENOUS LEUKEMIA

  Rabab Aly, Mohamed R. El-sharnoby, Adel A. Hagag

  e2011055

  2011-11-28

  https://doi.org/10.4084/mjhid.2011.055

  1925

  PDF: 775

  HTML: 1573

• PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA

  Annarosa Cuccaro, Francesca Bartolomei, Elisa Cupelli, Stefan Hohaus

  e2014053

  2014-07-04

  https://doi.org/10.4084/mjhid.2014.053

  3436

  PDF: 2026

  HTML: 7572

• THERAPEUTIC OPTIONS FOR PATIENTS WHO ARE NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY

  Elihu Estey

  e2013050

  2013-07-12

  https://doi.org/10.4084/mjhid.2013.050

  2232

  PDF: 776

  HTML: 1640

• THE TREATMENT OF ADVANCED-STAGE MYCOSIS FUNGOIDES AND SEZARY SYNDROME: A HEMATOLOGIST'S POINT OF VIEW.

  Antonio Giordano, Livio Pagano

  e2022029

  2022-02-27

  https://doi.org/10.4084/MJHID.2022.029

  2356

  PDF: 1072

  HTML: 392

• ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES

  Daniel Olson, Abraham Tareq Yacoub, Gelenis Domingo, John Norman Greene

  e2014068

  2014-08-28

  https://doi.org/10.4084/mjhid.2014.068

  2229

  PDF: 750

  HTML: 2144

  Untitled: 242

  Untitled: 169

  Untitled: 193

  Untitled: 171

  Untitled: 186

  Untitled: 199

  Untitled: 199

• BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

  Lorenzo Falchi, Jessica M Baron, Carrie Anne Orlikowski, Alessandra Ferrajoli

  e2016011

  2016-02-10

  https://doi.org/10.4084/mjhid.2016.011

  4412

  PDF: 1523

  HTML: 3723

• CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.

  Vincenzo De Sanctis

  e2020006

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.006

  4359

  PDF: 1555

  HTML: 465

• AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA: NON-RANDOMIZED STUDY WITH A MAXIMUM FOLLOW-UP OF MORE THAN 22 YEARS

  Grzegorz Helbig, Malgorzata Krawczyk-Kulis, Malgorzata Kopera, Krystyna Jagoda, Patrycja Rzepka, Aleksandra Majewska-Tessar, Marta Hejla, Slawomira Kyrcz-Krzemien

  e2014047

  2014-06-29

  https://doi.org/10.4084/mjhid.2014.047

  1594

  PDF: 936

  HTML: 2009

  Figure: 193

  Tables: 204

  ALL revision 1: 291

  response to reviewer: 198

• EARLY PREDICTORS OF RENAL DYSFUNCTION IN ?-THALASSEMIA MAJOR AND INTERMEDIA PATIENTS

  Azza A.G. Tantawy, Nagham El Bablawy, Amira A. M Adly, Fatma S E Ebeid

  e2014057

  2004-09-01

  https://doi.org/10.4084/mjhid.2014.057

  2008

  PDF: 972

  HTML: 3890

• INFECTIONS AND FOLLICULAR LYMPHOMA: IS THERE A LINK?

  Francesco Zallio, Giulia Limberti, Marco Ladetto

  e2017035

  2017-05-01

  https://doi.org/10.4084/mjhid.2017.035

  3308

  PDF: 1054

  HTML: 2319

• Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA

  Michele Puppi, Ilaria Sacchetti, Katia Mancuso, Paola Tacchetti, Lucia Pantani, ilaria Rizzello, Miriam Iezza, Marco Talarico, Enrica Manzato, Simone Masci, Roberta Restuccia, Simona Barbato, Silvia Armuzzi, Barbara Taurisano, Ilaria Vigliotta, Elena Zamagni

  e2025045

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.045

  1757

  PDF: 1306

  HTML: 577

• GASTROINTESTINAL MYELOID SARCOMA A CASE PRESENTATION AND CRITICAL REVIEW OF THE LITERATURE GASTROINTESTINAL MYELOID SARCOMA

  Pouyan Kheirkhah, Ana M. Avila-Rodriguez, Bartlomiej Radzik, Carlos Murga-Zamalloa

  e2021067

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.067

  1587

  PDF: 658

  HTML: 351

• REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY Real-world Assessment of Myeloma Patients as Candidates for CAR-T Therapy

  Ulrike Bacher, Simon Brechbühl, Barbara Jeker, Thomas Pabst

  e2021012

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.012

  1654

  PDF: 671

  HTML: 1265

• POEMS SYNDROME: AN UPDATE

  Andrea Nozza

  e2017051

  2017-09-01

  https://doi.org/10.4084/mjhid.2017.051

  3424

  PDF: 1696

  HTML: 1770

• FLUDARABINE-MELPHALAN-CAMPATH FOLLOWED BY UNMANIPULATED PERIPHERAL-BLOOD HAEMATOPOIETIC STEM CELLS CAN STILL CURE LYMPHOMA.

  Daniele Avenoso, Amal Alabdulwahab, Michelle Kenyon, Varun Mehra, Pramila Krishnamurthy, Francesco Dazzi, Ye Ting Leung, Sandra Anteh, Mili Naresh Shah, Andrea Kuhnl, Robin Sanderson, Piers Patten, Deborah Yallop, Antonio Pagliuca, Victoria Potter

  e2023041

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.041

  1664

  PDF: 752

  HTML: 243

• DIFFERENCES IN EX-VIVO CHEMOSENSITIVITY TO ANTHRACYCLINES IN FIRST LINE ACUTE MYELOID LEUKEMIA

  Juan Eduardo Megias-Vericat, David Martínez-Cuadrón, Joaquin Martínez López, Juan Miguel Bergua, Mar Tormo, Josefina Serrano, Ataulfo González, Jaime Pérez de Oteyza, Susana Vives, Belen Vidriales, Pilar Herrera, Juan Antonio Vera, Aurelio López Martínez, Adolfo De la Fuente, María Lourdes Amador, José Ángel Hernández-Rivas, María Ángeles Fernández, Carlos Javier Cerveró, Daniel Morillo, Pilar Hernández Campo, Julián Gorrochategui, Daniel Primo, José Luis Rojas, Margarita Guenova, Joan Ballesteros, Miguel Ángel Sanz, Pau Montesinos

  e2019016

  2019-02-26

  https://doi.org/10.4084/mjhid.2019.016

  2058

  PDF: 1148

  HTML: 322

• THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA

  Xenofon Papanikolaou, Bart Barlogie, Saad Usmani

  e2011047

  2011-10-24

  https://doi.org/10.4084/mjhid.2011.047

  2540

  PDF: 815

  HTML: 1743

• NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?

  Alessandro Corso, Silvia Mangiacavalli

  e2017053

  2017-08-18

  https://doi.org/10.4084/mjhid.2017.053

  3337

  PDF: 1740

  HTML: 1152

• HEPATITIS C VIRUS INFECTION AND LYMPHOMA

  Emmanuel Bachy, Caroline Besson, Felipe Suarez, Olivier Hermine

  e2010004

  2010-03-25

  https://doi.org/10.4084/mjhid.2010.004

  1086

  PDF: 577

  HTML: 7881

• Myeloid neoplasms with isolated isochromosome 17q: a yet to be defined entity

  Eleftheria Lamprianidou, Chryssoula Kordella, Menelaos Papoutselis, Zoi Bezyrgiannidou, Evangelia Nakou, Spyros Papamichos, Emmanouil Spanoudakis, Andreas Giannopoulos, Katerina Zoi, Ioannis Kotsianidis

  e2017066

  2017-11-01

  https://doi.org/10.4084/mjhid.2017.066

  2359

  PDF: 813

  HTML: 1248

• GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS

  Angela Stoddart, Megan E. McNerney, Elizabeth Bartom, Rachel Bergerson, David J. Young, Zhijian Qian, Jianghong Wang, Anthony A. Fernald, Elizabeth M. Davis, Richard A. Larson, Kevin P. White, Michelle M. Le Beau

  e2011019

  2011-05-16

  https://doi.org/10.4084/mjhid.2011.019

  2654

  PDF: 835

  HTML: 5367

• ROLE OF COMORBIDITIES IN OPTIMIZING DECISION-MAKING FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

  Mohamed L. Sorror, Rainer F. Storb

  e2010015

  2010-06-08

  https://doi.org/10.4084/mjhid.2010.015

  1040

  PDF: 656

  HTML: 2239

• HOW I TREAT NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA

  Giuseppe Avvisati

  e2011064

  2011-12-19

  https://doi.org/10.4084/mjhid.2011.064

  13329

  PDF: 1005

  HTML: 7306

• Validation of a New Scoring System for Treatment Failure in CML Patients on Tyrosine Kinase Inhibitors in a real world setting

  Andrea Mattozzi, Eugenio Galli, Francesco Autore, Ilaria Pansini, Patrizia Chiusolo, Simona Sica, Federica Sorà

  e2026013

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.013

  639

  PDF: 550

  Html: 91

• RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CHEMOIMMUNOTHERAPY, TREATMENT UNTIL PROGRESSION WITH MECHANISM-DRIVEN AGENTS OR FINITE-DURATION THERAPY?

  Antonio Cuneo, Robin Foà

  e2019024

  2019-02-27

  https://doi.org/10.4084/mjhid.2019.024

  2776

  PDF: 1694

  HTML: 391

• TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH SINGLE-AGENT ARSENIC TRIOXIDE

  Vikram Mathews, Ezhilarasi Chendamarai, Biju George, Auro Viswabandya, Alok Srivastava

  e2011056

  2011-11-28

  https://doi.org/10.4084/mjhid.2011.056

  3728

  PDF: 974

  HTML: 4492

• The INFLUENCE OF NUTRITION ON DISEASE SEVERITY AND HEALTH-RELATED QUALITY OF LIFE IN ADULTS WITH SICKLE CELL DISEASE A Prospective Longitudinal Study

  Sanaa Kamal, Moheyeldeen Mohamed Naghib, Jamaan Al Zahrani, Huda Hassan, Karim Abdel Aziz Moawado, Omar Arrahman

  e2021007

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.007

  2484

  PDF: 987

  HTML: 336

• INFECTIOUS RISKS AND COMPLICATIONS IN ADULT LEUKEMIC PATIENTS RECEIVING BLINATUMOMAB

  Wonhee So, Shuchi Pandya, Rod Quilitz, John Greene

  e2018029

  2018-05-01

  https://doi.org/10.4084/mjhid.2018.029

  3041

  PDF: 1109

  HTML: 367

• BACTERIAL BLOOD STREAM INFECTIONS NEGATIVELY IMPACT ON OUTCOME OF PATIENTS TREATED WITH ALLOGENEIC STEM CELL TRANSPLANTATION: 6 YEARS SINGLE-CENTRE EXPERIENCE

  Michele Malagola

  e2017036

  2017-06-20

  https://doi.org/10.4084/mjhid.2017.036

  4245

  PDF: 875

  HTML: 1115

• GREEK CONSENSUS ON CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATMENT

  Sotirios Sachanas, Theodoros Vassilakopoulos, Maria Angelopoulou, sotirios Papageorgiou, Emmanouil Spanoudakis, Maria Bouzani, Maria Dimou, Panagiotis Panagiotidis

  e2025014

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.014

  1479

  HTML: 167

  PDF: 902

• UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)

  José Luis Piñana, Estela Giménez, Lourdes Vázquez, María Ángeles Marcos, Manuel Guerreiro, Rafael Duarte, Ariadna Pérez, Carlos de Miguel, Ildefonso Espigado, Marta González-Vicent, María Suarez-Lledó, Irene García-Cadenas, Rodrigo Martino, Angel Cedillo, Monserrat Rovira, Rafael de la Cámara, David Navarro, Carlos Solano

  e2024065

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.065

  4233

  Suppl. Files: 1200

  PDF: 1119

  Html: 252

• QUALITY OF LIFE ASSESSMENT IN MULTIPLE MYELOMA PATIENTS UNDERGOING DOSE-REDUCED TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION

  Alhossain A. Khalafallah, Kristina McDonnell, Hizb U. Dawar, Iain Robertson, David Woods

  e2011057

  2011-11-28

  https://doi.org/10.4084/mjhid.2011.057

  1444

  PDF: 716

  HTML: 1385

  cover letter: 223

• APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  Tadeusz Robak

  e2010011

  2010-05-07

  https://doi.org/10.4084/mjhid.2010.011

  1702

  PDF: 667

  HTML: 2442

• CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES

  Ugo Testa, Prof. Patrizia Chiusolo, Dr. Elvira Pelosi, Dr. Germana Castelli, Giuseppe Leone

  e2024031

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.031

  2269

  PDF: 2100

  HTML: 212

• EBV IN HODGKIN LYMPHOMA

  Giuseppina Massini, Doerte Siemer, Stefan Hohaus

  e2009013

  https://doi.org/10.4084/mjhid.2009.013

  1717

  PDF: 620

  HTML: 14119

• Guest Editor: Pellegrino Musto HOW FIRST LINE THERAPY IS CHANGING IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS

  Yasmine Houbaida, Maria Livia Del Giudice, Sara Galimberti, Gabriele Buda

  e2025026

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.026

  2058

  PDF: 1723

  HTML: 328

• TDT Positive High-Grade Lymphoma with Myc, BCL2 And BCL6 Rearrangements: a Review of Diagnosis and Treatment TDT POSITIVE HIGH-GRADE LYMPHOMA WITH MYC, BCL2 AND BCL6 REARRANGEMENTS.

  Aditi Singh, MD, Ishaq Asghar, MD, Laura Kohler, DO, Hosam Hakim, MD, Daniel Snower, MD, Daniel Lebovic, MD

  e2022018

  2022-02-27

  https://doi.org/10.4084/MJHID.2022.018

  1968

  PDF: 815

  HTML: 562

• CHRONIC MYELOGENOUS LEUKEMIA (CML) IN THE ELDERLY

  Lodovico Balducci

  e2014037

  2014-05-31

  https://doi.org/10.4084/mjhid.2014.037

  2948

  PDF: 1142

  HTML: 3069

• OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE

  Grzegorz Helbig, Grazyna Bober, Marek Seweryn, Ryszard Wichary, Andrzej Tukiendorf, Lech Sedlak, Tomasz Oleksy, Slawomira Kyrcz-Krzemien

  e2015003

  2015-01-01

  https://doi.org/10.4084/mjhid.2015.003

  2319

  PDF: 1085

  HTML: 2025

  Characteristic of study group: 217

• BETA THALASSEMIA MAJOR IN A DEVELOPING COUNTRY: EPIDEMIOLOGICAL, CLINICAL AND EVOLUTIONARY ASPECT

  Mohamed Bejaoui, Naouel Guirat

  e2013002

  2013-01-01

  https://doi.org/10.4084/mjhid.2013.002

  1694

  PDF: 922

  HTML: 2527

• CURING HEMOGLOBINOPATHIES: CHALLENGES AND ADVANCES OF CONVENTIONAL AND NEW GENE THERAPY APPROACHES.

  Irene Motta, Valentina Ghiaccio, Andrea Cosentino, Laura Breda

  e2019067

  2019-10-30

  https://doi.org/10.4084/mjhid.2019.067

  3043

  PDF: 1885

  HTML: 895

• THE COURSE OF HEPATITIS C INFECTION AND RESPONSE TO ANTI-VIRAL THERAPY IN PATIENTS WITH THALASSEMIA MAJOR AND HEPATITIS C INFECTION: A LONGITUDINAL, PROSPECTIVE STUDY.

  Sanaa Kamal, Sara Abdelhakam, Dr., Dahlia Ghoraba, Mohamad Amer Mohsen, Ahmed Abdelsalam, Huda Hassan, Leila Nabeigh

  e2019060

  2019-10-30

  https://doi.org/10.4084/mjhid.2019.060

  1478

  PDF: 1084

  HTML: 215

• TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment

  Alessandro Buonomo, Eleonora Nucera, Marianna Criscuolo

  e2022040

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.040

  2200

  PDF: 1599

  HTML: 666

• CHLORAMBUCIL PLUS RITUXIMAB AS FRONT-LINE THERAPY IN ELDERLY/UNFIT PATIENTS AFFECTED BY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A SINGLE-CENTRE EXPERIENCE.

  Luca Laurenti, Barbara Vannata, Idanna Innocenti, Francesco Autore, Francesco Santini, Nicola Piccirillo, Tommaso Za, Silvia Bellesi, Sara Marietti, Simona Sica, Dimitar G. Efremov, Giuseppe Leone

  e2013031

  2013-05-01

  https://doi.org/10.4084/mjhid.2013.031

  3317

  PDF: 928

  HTML: 1549

  Fig.1 CHL-R paper: 237

  Fig 2 CHL-R paper: 263

• HEMATOPOIETIC STEM CELL TRANSPLANTATION IN EGYPT CHALLENGES AND OPPORTUNITIES

  Hossam Kamel Mahmoud, Gamaleldin Mohamed Fathy, Alaa Elhaddad, Omar Abdelrahman Fahmy, Mohamed Abdelmooti, Raafat Abdelfattah, Mahmoud Tarek Sayed Ahmed Bokhary

  e2020023

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.023

  1923

  PDF: 1008

  HTML: 871